China Resources Double-Crane Pharmaceutical (600062.SH) subsidiary Azilsartan raw material drug has obtained a notice of approval for the application for listing of chemical raw materials.

China Resources Double-Crane Pharmaceutical (600062.SH) announced recently that its holding subsidiary Zhejiang XinSaiKe Pharmaceutical Co., Ltd. (referred to as "Zhejiang XinSaiKe") has received the "Notice of Approval for Application for Listing of Chemical Raw Materials for Pharmaceuticals" (notification number: 2025YS00186) issued by the National Medical Products Administration. Azilsartan is an angiotensin II receptor antagonist (ARB) for the treatment of hypertension. Zhejiang XinSaiKe has obtained the "Notice of Approval for Application for Listing of Chemical Raw Materials for Pharmaceuticals" for Azilsartan, indicating that the raw material meets the national standards for drug evaluation technology, and can be produced and sold in the domestic market after passing the GMP compliance inspection. This will help further enrich the company's product line and enhance its market competitiveness.